[
    [
        {
            "time": "",
            "original_text": "【医药生物行业】2019年下半年投资策略：新旧动能转换期, 新机制下再平衡",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "新旧动能转换",
                    "新机制",
                    "再平衡"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【医药生物行业】2019年下半年投资策略：新旧动能转换期, 新机制下再平衡",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "光大证券：寻找政策免疫及新机制下的确定性机会",
            "features": {
                "keywords": [
                    "光大证券",
                    "政策免疫",
                    "新机制",
                    "确定性机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "光大证券：寻找政策免疫及新机制下的确定性机会",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "医药生物 | 改革阵痛期，寻找结构调整中的机遇",
            "features": {
                "keywords": [
                    "医药生物",
                    "改革阵痛期",
                    "结构调整",
                    "机遇"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物 | 改革阵痛期，寻找结构调整中的机遇",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]